Introduction
Transferrin receptor (TfR, CD71) is a cell membraneassociated glycoprotein involved in the cellular uptake of iron and in the regulation of cell growth (Neckers and Trepel, 1986) . The elevated levels of TfR in malignancies, in addition to its relevance in cancer and its extracellular accessibility, make this molecular an excellent antigen for the therapy of cancer using antibodies (Daniels et al., 2006) . Therefore, a large series of TfR-specific monoclonal antibodies (mAbs) has been developed and used as one of therapeutic approaches to killing malignant cells in vitro and in vivo (Trowbridge et al., 1981; Domingo et al., 1985; Ng et al., 2002) . We previously reported that 7579 mAb, a murine mAb against surface TfR on human tumor cells, showed excellent anti-tumor activities in vitro (Ye et al., 2006) . However, due to its immunogenicity and poor ability to recruit immune effector mechanisms, murine mAb evaluated in the clinic is limited (Adams and Weiner, 2005 ). An attempt to overcome these hurdles is to generate chimeric mAbs that contain human Fc domains and retain targeting specificity by incorporating portions of the murine variable regions.
In most cases, chimeric mAbs are generated in the mammalian cell expression system. However, the yield of transient expression in this expression system is usually low, and achieving stable expression requires time-consuming selection procedures (Liang et al., 2001) . The prokaryotic expression system, despite offering the quickest solution for the expression of foreign genes, is not suitable to produce complete functional IgG molecules, since this expression system cannot provide appropriate folding disulfide bond formation and several post-translational modifications (Hasemann and Capra, 1990) . This suggests that a whole and functional IgG diheterotetramer can only be achieved in eukaryotic systems. Thus, the baculovirus/insect cell expression system, as one of the most popular eukaryotic expression systems, becomes the candidate for the production of functional IgG. Compared with the mammalian cell expression system and the prokaryotic expression system, the baculovirus/insect cell expression system combines the advantages of time saving, correct protein folding and stable and large scale expression (Hasemann and Capra, 1990) . More importantly, this system has already been established as a reliable system for the production of complete chimeric, humanized or human IgG that is similar to native molecule both structurally and functionally (Poul et al., 1995; Tan and Lam, 1999; Bès et al., 2001) .
Mating-assisted genetically integrated cloning (MAGIC) draws attention as a highly engineered in vivo cloning method. This strategy utilizes bacterial mating, in vivo sitespecific endonuclease cleavage and homologous recombination to catalyze the transfer of a DNA fragment between a donor vector in one bacterial strain and a recipient plasmid in a separate bacterial strain (Li and Elledge, 2005) . In brief, the MAGIC procedure only requires the simple mixing of bacterial strains, which will significantly save time, effort and expense. Therefore, this strategy facilitates the rapid and high-throughput production of recombinant DNA molecules for expression in multiple organisms. We previously reported a robust and scalable system to generate recombinant adenovirus based on the MAGIC strategy (Tan et al., 2006) and considered that this strategy might be used in the highefficient production of other recombinant viruses, including recombinant baculovirus.
Based on above, we herein applied the MAGIC strategy to the genetic engineering of a mouse/human chimera derived from 7579 mAb in the baculovirus/insect cell expression system. Moreover, a series of experiments was performed to characterize the resultant chimeric antibody both structurally and functionally.
Materials and methods

Cell culture
Hybridoma cell line 7579, which stably expressed anti-TfR mAb 7579, was maintained in our laboratory. Human hepatoma cell line HepG2, human breast cancer cell line MCF-7, human erythroleukemia cell line K562, human myeloid leukemia cell line HL-60, human melanoma cell line A375 and human cervix cancer cell line HeLa were maintained in DMEM supplemented with 10% fetal bovine serum and incubated at 378C in a humidified atmosphere containing 5% CO 2 . Spodoptera frugiperda Sf9 cells were maintained in Grace's medium containing 10% fetal bovine serum and cultured at 278C in a non-humidified environment.
Bacteria, plasmids, primers and restriction enzymes
Escherichia coli strains DH10b and BUN21, the helper plasmid pML300 and the donor plasmid pMAGIC1 were kindly donated by Prof. Stephen J. Elledge from the Harvard Medical School in Boston (MA, USA). We modified the donor plasmid and obtained a new donor vector pMGA-DkG (Fig. 1A) . The fragment of interest in the vector pMGA-DkG was flanked by two different 50 bp homology regions H3 and H4, and these two homology regions in turn were flanked with two separate I-SceI sites. The recipient vector pBac-pheS, which contained two I-SceI-linked H3 and H4 sites and pheS selective marker, was constructed based on the Bac-to-Bac system, and propagated in E.coli strain BUN21. The vectors pMD-19T, pcDNA3.1 and pUC19 were purchased from Invitrogen (CA, USA). Primers used for PCR amplification in this study were listed in Table I and synthesized by Invitrogen Biotechnology Co., Ltd. The M13/pUC sequencing primers and restriction enzymes including XhoI, BamHI, EcoRI, SalI, NheI and HindIII were all purchased from Fermentas (MD, USA).
PCR amplification of the genetic elements for chimeric antibody
Total RNA was isolated from 7579 hybridoma cells and human peripheral blood mononuclear cells (PBMCs) with TRIzol Reagent (Invitrogen). The first cDNA strand was synthesized by using Oligo-(dT) 15 primer and reverse transcriptase (Roche Diagnostics, Switzerland). With primers (Table I) , the heavy and light variable region genes of 7579 mAb containing leader sequence, the constant region genes of human IgG1 heavy chain (C H ) and human IgG k chain (C L ) were obtained by PCR amplification. All amplified PCR fragments were cloned into pMD-19T vector for sequence determination.
Construction of the donor vectors pMGA-H and pMGA-L The donor vectors pMGA-H and pMGA-L, containing the full DNA fragments of recombinant heavy and light chains, were constructed as follows. The fragment of V L was cloned into the cloning sites NheI/HindIII of pcDNA3.1 vector to result in the plasmid pcDNA-V L . The fragment of C L was then cloned into the resulting plasmid through HindIII/EcoRI and yielded the light chain expression vector pcDNA-L. In a similar way, the fragments of V H and C H were cloned into the vector pUC19 through the cloning sites SalI/BamHI and BamHI/EcoRI, and resulted in the heavy chain expression vector pUC-H. According to the sequence information of the donor vector pMGA-DkG, the cloning sites of EcoRI/XhoI and BamHI/XhoI were induced into the chimeric heavy and light chains through PCR amplification with primers H-f/H-r and L-f/L-r ( Table I ). The PCR products of the full length heavy and light chains containing the according cloning sites were then cloned into the frame bone vector pMGA-DkG, respectively. Above steps resulted in two donor vectors pMGA-H and pMGA-L.
Generating the recombinant bacmids bac-H and bac-L by MAGIC
The donor strain DH10b, containing the donor vector pMGA-H or pMGA-L, was grown in Luria -Bertani (LB) broth containing ampicillin (100 mg/ml). The recipient strain BUN21, which contained the helper plasmid pML300 and the recipient vector pBac-pheS, was grown in LB broth in the presence of spectinomycin (50 mg/ml), kanamycin (50 mg/ml) and glucose (0.2% w/v) overnight. The recipient strain was washed twice with 2 volume of LB broth the next day. The donor and recipient strains were separately diluted to 1:100 with LB broth containing 0.2% w/v rhamnose and grown at 308C for 2 h to A 600 of 0.15 -0.25, and then the donor and recipient strains were mixed to a ratio of 1:1 based on their A 600 in the presence of 0.2% w/v L-arabinose. The mixture was incubated at 378C for 2 h without shaking, and then for a further 2 h with shaking. The recombinant culture was diluted at the ratio of 1:100, plated on the selective plates containing kanamycin (50 mg/ml), ampicillin (100 mg/ ml), 10 mM Cl-Phe and 0.2% w/v L-arabinose, and finally incubated at 428C overnight. Single colony was selected from the above selective plates the next day and identified by colony PCR with specific primers.
Expression and purification of chimeric antibody
The recombinant bacmids bac-H and bac-L were transfected into Sf9 cells by using Cellfectin Transfection Reagent (Invitrogen), respectively. Recombinant baculovirus Bac-H and Bac-L were harvested from supernatants of Sf9 cells culture medium at 72 h post-transfection, and subsequent plaque purification was performed to obtain pure and high titer recombinant virus. Sf9 cells were co-infected with the recombinant viruses Bac-H and Bac-L at the optimal m.o.i. of 10, and then incubated at 278C until $50-60% of dead cells were observed ($2 days post-infection). The supernatants of co-infected Sf9 cells were harvested and clarified by centrifugation. After filtered through 0.45 mm filters, the samples were purified with a HiTrap Protein A HP (GE Healthcare, Sweden) according to the manual of procedure. All purified chimeric antibody samples were analyzed under The procedures for generating recombinant bacmids, bac-H and bac-L, through the MAGIC strategy were summarized. The donor and recipient vectors were generated as described in the Materials and methods section, and then transformed into the donor strain DH10b and the recipient strain BUN21. The DNA fragment of interest in the donor vector and the negative marker (pheS) in the recipient vector were both cut down by an intro-encoding rare endonuclease I-SceI, and then the recombination events intermediated by the red and gam recombinase were stimulated. The recombinant bacmids was generated. (D) Identification of recombinant bacmids bac-H and bac-L was performed by colony PCR with specific primers. With the M13/pUC forward and revised primers, we amplified the colonies, which probably contained the genes of chimeric heavy chain (lanes 1 -4 and 8 -10) or light chain (lanes 5 -7, 11 and 12); with the M13F and H-r (L-r) primers, we re-amplified the above colonies (chimeric heavy chain: lanes 13-16 and 20-22; chimeric light chain: lanes 17-19, 23 and 24). All of PCR products were electrophoresed on 1% agarose gels and stained with ethidium bromide. DNA markers were indicated. denaturing and non-denaturing condition by 10% polyacrylamide gel electrophoresis (PAGE). Total protein staining was achieved with Coomassie Brilliant Blue R250 (Serva, Heidelberg, Germany). In immunoblotting, the protein samples were then transferred onto nitrocellulose membranes. The membranes were blocked with 5% defatted milk and probed with the mixtures of HRP-conjugated goat antihuman IgG Fc antibody and HRP-conjugated goat antihuman k chain antibody (Southern Biotech, USA). The membranes were then incubated with enhanced chemiluminesecent substrate (Santa Cruz Biotechnology) before being exposed to film.
Antigen-binding assay
TfR-overexpressing tumor cells HepG2, MCF-7, A375, HL-60, K562 and HeLa were used as target cells. Briefly, cells (2 Â 10 5 ) were resuspended in phosphate-buffered saline supplemented with 3% bovine serum albumin and then incubated at 48C for 1 h with chi7579 mAb, 7579 mAb (used as positive control), non-specific mouse IgG (used as negative control 1), non-specific human IgG (used as negative control 2) and DMEM medium (used as blank control), respectively. After washing, cells were stained with FITC-conjugated goat anti-human IgG or FITC-conjugated goat anti-mouse IgG (Southern Biotech) at 48C for 30 min. The samples were washed again and analyzed by flow cytometry (Beckton-Dickinson FACScalibur, USA).
Competitive binding assay
HepG2 cells (1 Â 10 6 ) were incubated with subsaturating concentration of 7579 mAb and increasing concentrations of competing antibody (chi7579 mAb) at 48C for 1 h. Then, the cells were stained by FITC-conjugated goat anti-mouse IgG at 48C for 30 min. The alterations of the mean channel fluorescence were analyzed by flow cytometry. Non-specific human IgG was used as irrelevant control IgG. The affinity constant (K a ) of chi7579 mAb was calculated as described by Friguet et al. (Friguet et al., 1985) . Similarly, when 7579 mAb was used as competitor, chi7579 mAb, stained with FITC-conjugated goat anti-human IgG, was used as labeled-antibody, and non-specific mouse IgG was used as irrelevant control IgG. The K a of 7579 mAb was obtained as described above.
Antibody-dependent cellular cytotoxicity assay
Human PBMCs were purified from the whole blood of healthy volunteers using Ficoll-Paque Plus (GE Healthcare) and used as effector cells. TfR-overexpressing tumor cells HepG2 and MCF-7 were used as target cells. Target cells were seeded in triplicate at 1 Â 10 4 per well in 96-well tissue culture plates, and various concentrations of chimeric antibody or control IgG (non-specific human IgG) were added. Effector cells were then added at effector to target (E/T) ratio of 50:1. After 6 h incubation, 100 ml supernatants were harvested, and the antibody-dependent cellular cytotoxicity (ADCC) activity was examined by LDH release kit (Biovision, USA). The optical density (OD) was measured at 490 nm with ELISA plate reader (Genios TECAN, Austria). The rates of cell lysis were calculated by the following equation: lysis rate (%) ¼ (E 2 S)/(M 2 S) Â 100, where E is the release in the test sample (the value of OD 490nm in the supernatants from target cells incubated with effector cells and test antibody), S is the spontaneous release (the value of OD 490 nm in the supernatants from target cells incubated with medium alone), and M is the maximum release (the value of OD 490 nm in the supernatants from target cells lysed with 0.1% w/v NP-40).
Complement-dependent cytotoxicity assay
TfR over-expressing tumor cells HepG2 and MCF-7 were used as target cells. Target cells were seeded in triplicate at 1 Â 10 5 per well in 96-well tissue culture plates, and then incubated with various concentrations of chimeric antibody in the presence of 100 mL baby rabbit complement (Cedarlane, Canada) at 378C for 2 h. Non-specific human IgG was used as control IgG. The complement-dependent cytotoxicity (CDC) activity was evaluated by MTT cell vitality assay kit (Biotium, USA), and the optical density (OD) was measured at 570 nm with ELISA plate reader. The rates of cell lysis were calculated by the following formula: lysis rate (%) ¼ (1 2 E/S) Â 100, where E is the value of OD 570 nm in chi7579 mAb-or control IgG-treated groups and S is the value of OD 570 nm in medium treated-groups (blank control).
Statistical analysis
Statistical significance of the data was calculated by ANVOA or Student's t-test. A significance level of P , 0.01 was chosen. 
Results
Generating recombinant bacmids bac-H and bac-L by the MAGIC strategy
In the previous study, we constructed the adenovirus donor plasmid pRTRA based on the donor plasmid pMAGIC1 (Tan et al., 2006) . Here, we replaced the CMV promoter with the polyhedrin promoter and constructed the baculovirus donor vector pMGA-DkG. The detailed map of this new vector was shown in Fig. 1A . Through RT -PCR and subcloning procedures, variable regions from murine 7579 mAb and constant regions from human IgG1 were spliced into the whole heavy and light chains of chimeric antibody. As illustrated in Fig. 1B , DNA sequence analysis verified that chimeric light chain had 100% sequence identity for 7579 mAb V L joined to human k constant region, and chimeric heavy chain had 100% sequence identity for 7579 mAb V H joined to human g1 constant region. By using EcoRI/XhoI and BamHI/XhoI double digestion, the above chimeric heavy and light chains were ligated into the donor vector pMGA-DkG, respectively. The resultant plasmids were designated as pMGA-H and pMGA-L.
The following procedures of generating recombinant bacmids through the standard MAGIC strategy were summarized in Fig. 1C . Briefly, the donor strains containing the donor vector pMGA-H or pMGA-L were mixed with the recipient strains containing the helper plasmid pML300 and the recipient vector pBac-pheS. In the presence of L-arabinose and rhamnose, the fragments of the donor vector, containing the genes of chimeric heavy or light chain, were cut by I-SceI and transferred to the recipient vector by in vivo homologous recombination. The mixed bacteria were plated on the plates containing kanamycin, ampicillin and Cl-Phe, and single colonies selected from the above selective plates would be all homologous recombinants theoretically. Since the bacmid DNA was .135 kb and verification of the insertion of the gene of interest was difficult in using classical restriction endonuclease digestion analysis, we further identified positive colonies containing the genes of chimeric heavy or light chain by colony PCR using specific primers. With the M13/pUC forward and revised primers, we amplified the colonies which probably contained the genes of chimeric heavy chain or light chain. The regions of amplification mainly included gentamicin resistance gene ($1.5 kb), polyhedrin promoter ($0.3 kb), heavy/light chain gene ($1.5/0.75 kb), SV40-ployA ($0.46 kb) and ampicillin resistance gene ($1.1 kb). Thus, $5.4 or 4.7 kb amplified fragments were observed in Fig. 1D . Furthermore, with the M13F and H-r (L-r) primers, we re-amplified the above colonies. The regions of amplification mainly consisted of gentamicin resistance gene, polyhedrin promoter and heavy/light chain gene. About 3.38 or 2.6 kb amplified fragments were observed, which were identical with the theoretical values (Fig. 1D) . The colonies, which could be amplified by the above two groups of specific primers, were regarded as positive colonies. In the seven screened colonies, which probably contained the genes of chimeric heavy chain, there were two negative colonies (lanes 1 and 8, Fig. 1D) ; and all screened colonies, which probably contained the genes of chimeric light chain, were recombinants. These data indicated that the genes of chimeric heavy and light chains were inserted into the bacmid DNA and the resultant recombinant bacmids were designated as bac-H and bac-L, respectively.
Expression and purification of baculovirus-expressed chimeric antibody
The supernatants of Sf 9 cells co-infected by recombinant baculoviruses Bac-H and Bac-L for 48 h were collected and purified by binding to Protein A-sepharose. The purified product was detected by PAGE and immunoblotting. Heavy and light chains of the expected molecular weights, $60 and 30 kDa, were observed under denaturing condition of PAGE ( Fig. 2A) , and then verified by immunoblotting using the mixtures of HRP-conjugated goat anti-human IgG Fc antibody and HRP-conjugated goat anti-human k chain antibody (Fig. 2B) . Moreover, in non-denaturing PAGE, the purified chimeric antibody revealed a single band, corresponding to the expected molecular weight of a correctly processed whole human IgG (Fig. 2C) . Taken together, these results demonstrated that the chimeric light and heavy chains, containing human IgG1 constant regions, were correctly processed and assembled in insect cells, and then secreted into the mediums as heterodimeric H 2 L 2 immunoglobulins. The resultant chimeric antibody was designated as chi7579 mAb.
Evaluating the antigen-binding profile of baculovirus-expressed chi7579 mAb
To determine whether chi7579 mAb could bind to surface TfR on tumor cells, we performed the antigen-binding assay by flow cytometry. As shown in Fig. 3Aa, chi7579 mAb specifically bound to TfR-overexpressing tumor cells HeLa, with the cell-binding rate close to that of its parental murine 7579 mAb, whereas controls, including DMEM medium alone and control IgG, did not show increased binding rates. Similar results were observed in MCF-7, A375, HL-60, HepG2 and K562 cells, which also expressed TfR at high levels (Fig. 3Ab , *P , 0.01 and **P , 0.01). Furthermore, the specificity and affinity of chi7579 mAb binding to target antigen were assessed by competitive binding assay. Chi7579 mAb could effectively compete with its parental mouse antibody for binding to HepG2 cells (Fig. 3B) . The affinity constant (K a ) of chimeric antibody was similar to that of 7579 mAb. These results indicated that the baculovirus-expressed chi7579 mAb possessed specificity and affinity similar to that of its original murine antibody.
Evaluating the Fc-binding profile of baculovirus-expressed chi7579 mAb
Using LDH release assay, we examined the ADCC activity of chi7579 mAb against TfR-overexpressing tumor cells. As indicated in Fig. 4A , in the presence of human PBMCs and at E/T ratio of 50:1, chi7579 mAb induced the lysis of HepG2 cells and MCF-7 cells in a dose-dependent manner. No obvious cytotoxicity was observed in control IgG. Furthermore, by MTT assays, we detected the CDC activity of chi7579 mAb against the above target cells. In the presence of rabbit complements, chi7579 mAb could mediate CDC against both HepG2 cells and MCF-7 cells in a dosedependent manner (Fig. 4B , *P , 0.01, **P , 0.01 and ***P , 0.01). No CDC against the above tumor cells was induced by control IgG. These results revealed that in the presence of effector cells or complements the baculovirusexpressed chi7579 mAb could induce ADCC and CDC against TfR-overexpressing tumor cells through its humanized Fc domains. 
Discussion
Antibody-based therapeutics has emerged as important component of therapies for an increasing number of human malignancies (Adams and Weiner, 2005) . In malignant diseases, the use of anti-TfR antibody has largely focused on killing of target cancer cells (Daniels et al., 2006) , e.g. through CDC, ADCC, apoptosis and cell cycle arrest. To this end, both antigen-binding and Fc-binding capacities of anti-TfR antibodies are critical for inducing biological effects. In this study, we generated a complete chimeric IgG1 against surface TfR on human tumor cells in the baculovirus/insect cell expression system. What we were concerned about was whether the biological functions of baculovirus-expressed antibodies were similar to those of mammalian-expressed antibodies, as already described for other insect cell-derived antibodies directed against various antigens (Carayannopoulos et al., 1994; Liang et al., 2001; Lieby et al., 2001) . Results of antigen-binding assay revealed that the baculovirus-expressed chi7579 mAb had identical fluorescence pattern toward TfR over-expressing tumor cells with its parental murine mAb, and further analysis of competitive binding assay showed that this chimera and its parental mAb had similar affinity for target antigen. Together with an efficient recognition of the heavy and light chains of chi7579 mAb in immunoblotting, we could argue that the baculovirus-expressed chi7579 mAb was correctly processed and remained the identical antigen-binding activity to that of its parental murine antibody. On the other hand, in order to obtain the maximum Fc-dependent biological functions, human C H gene, preinstalled in pMGA-H vector used in this study, was designed to encode for hinge residues Leu 234 to Ser 239 and Asp 265 , Asp 270 , Asn 297 (Fc carbohydrate binding) and Pro 329 residues, which already were characterized as affecting Fcg receptor and C1q binding (Morgan et al., 1995; Isaacs et al., 1998; Shields et al., 2001; Presta et al., 2002) . Other residues, such as Glu 318 , Lys 320 and Lys 322 , also described as being involved in C1q binding (Tao et al., 1993; Isaacs et al., 1998) , were present in our construction (data not shown). In other words, the baculovirus-expressed chi7579 mAb contained all key amino acid residues involved in CDC and ADCC functions. Because insect cells do not perform certain carbohydrate trimming functions and do not process the sugars to add complex residues such as terminal sialic acid and galactose, the baculovirus-expressed antibodies may differ slightly in glycosylation from their mammalian counterparts (O'Reilly et al., 1994) . As shown in previous studies, however, these differences do not affect important IgG activities, including complement lysis activity and antibody-dependent cell-medicated cytotoxicity (Boyd et al., 1995) . In our study, we demonstrated that chi7579 mAb could efficiently induce ADCC and CDC against HepG2 and MCF-7 cells in the presence of PBMCs or complements. These results were consistent with the studies mentioned above and further indicated that whatever differences insect cell-derived antibodies might possess, these did not appear to have negative effect on common biological functions of the antibodies.
Although insect cells are used widely for the production of various recombinant proteins, the system is not yet ideal for the production of pharmaceutical-quality glycoproteins. One of the major reasons is due to differences in the glycosylation pattern between insect cell-expressed glycoproteins and those obtained from mammalian hosts. Especially, a(1,3)-linked fucose attached to the innermost GlcNAc is indicated as a potential epitope that caused allergenic reactions in human (Prenner et al., 1992; Wilson et al., 1998; Hemmer et al., 2001; Wilson et al., 2001; Bencúrová et al., 2004) . This type of modification of N-glycans in insect cells will be a limitation to the use of some lepidopteran insect cells for expressing human glycoproteins. Considering this limitation, we selected Sf9 cells as hosts for expressing recombinant antibody in our study. Sf9 cells are probably the most widely used insect cell line and its glycosylation patterns are widely studied (Voss et al., 1993; Ogonah et al., 1996; Hooker et al., 1999; Rudd et al., 2000; Hemmer et al., 2001 ). More importantly, several studies demonstrated that human interferon v1 expressed in Sf9 cells showed no a(1,3)-fucosylated N-glycan (Voss et al., 1993) , and Sf9 cells did not have detectable a(1,3)-fucosyltransferase activity (Ogonah et al., 1996; Rudd et al., 2000) . We therefore considered that the application of Sf9 cells as hosts would facilitate reducing the immunogenicity of chi7579 mAb. Of course, besides the correct choice of cell line, there are other strategies, including some forms of genetic and metabolic engineering for insect cells, in production of 'humanized' recombinant glycoprotein (Altmann et al., 1999) . Further work is needed in order to analyze the glycosylation patterns of chi7579 mAb when compared with human IgG and to determine how to apply the above strategies to further reducing its immunogenicity caused by the differences in glycosylation pattern.
In this study, we applied the MAGIC strategy to the construction of chimeric antibody. This novel strategy developed involved two major steps. First, the genes of interest were cloned into the donor vector pMGA-DkG. Second, the donor and the recipient bacteria were mixed for mating, and the recombinants were selected by using kanamycin, ampicillin and Cl-Phe. PCR with specific primers was performed for further identification. It is well known that many standard recombinant baculovirus vector systems, such as the Bac-to-Bac baculovirus expression system, have been established (Luckow et al., 1993) . Compared with the above conventional methods, this approach described here has several advantages. First, the level of background non-recombinants was low. Rare non-recombinant events were selected against using a combination of additional genetic strategies, including selection for growth of recipient plasmids in the presence of constitutive I-SceI, placing the negative selectable marker pheS G294 on the recipient plasmid, placing the lacO element on the transfer fragment and using the proper reporter recipient strain (Li and Elledge, 2005) . In our experiments, we selected seven Bac-H and five Bac-L recombinant colonies from the representative plates and only two colonies were identified as non-recombinants. Second, the positive selection by antibiotics, the negative selection by Cl-Phe and the ability to bypass further identification steps made the screening of recombinants simple and efficient.
Third, the system has potential for the modification of any baculovirus sequences, especially for the high-throughput construction of recombinant baculoviruses. Therefore, the MAGIC strategy shows favorable application prospects in antibody-engineering, especially in the rapid generation of humanized or chimeric mAbs.
In conclusion, we described the generation of baculovirus-expressed chimeric anti-TfR IgG1 antibody (chi7579 mAb) based on the MAGIC strategy. Importantly, the resultant chimeric antibody, considering its in vitro activity (i.e. the antigen-specific binding of its variable regions and the tumor-specific lysis mediating by its Fc domains), might be a useful therapeutic agent for cancer immunotherapy. Moreover, the MAGIC strategy, facilitating the rapid generation of chimeric mAbs, could have a promising future for application in antibody engineering.
